200 Boston Avenue - Medford, MAMedford, MA Seventh Sense Biosystems (7SBio) is relocating from Cambridge’s Kendall Sq. to Cummings Properties’ 200 Boston Ave. building. The firm, which develops blood collection and diagnostic platforms, has grown steadily, moving three times since its founding in 2008.
Cummings Properties leasing manager Derek Cook worked with Mark Winters of Cushman & Wakefield to find the ideal space for 7SBio. The privately held medical technology company will move this month into its new 9,000 s/f suite, which is a combination of clean room, lab, and office space.
“It’s not at all unusual for businesses to migrate outside the city as they grow,” said Cook. “The labs throughout our suburban portfolio provide a value that allows firms to save significantly on rent and dedicate more resources to research and development. We were pleased to be able to satisfy Seventh Sense Biosystems’ immediate need for a clean room for manufacturing—something that is essential to its processes. We also have the capacity in our 10 million s/f portfolio to allow the company to expand in the future.”
7SBio is best known for its proprietary Touch Activated Phlebotomy (TAPTM) technology platform, which draws blood in a virtually painless one-step process, reducing the discomfort and anxiety that often accompany blood based diagnostics, according to CEO Howard Weisman.
“The facility at 200 Boston is the right combination of quality laboratory and manufacturing space, value, and access to the entire metro area that we were looking for as we begin to commercialize our first products in 2016,” said Weisman.
The company announced in August that it has been granted a total of seven patents in the U.S. and Europe with many more under review around the world.
Situated just north of Cambridge, Cummings Properties’ 196/200 Boston Ave. campus is home to more than 20 businesses, including a dozen life sciences firms and Tufts University’s Bio-cluster Lab.